Galmed Pharmaceuticals Ltd (GLMD) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Galmed Pharmaceuticals Ltd   (NASDAQ: GLMD)


Galmed Pharmaceuticals Ltd 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Galmed Pharmaceuticals Ltd 's ROA in the fourth quarter of 2025?
Galmed Pharmaceuticals Ltd achieved a return on average assets (ROA) of 1.95 % in its fourth quarter of 2025, which is below Galmed Pharmaceuticals Ltd 's average return on assets, which stands at 7.94%.

ROA fell compared to the third quarter of 2025, despite the net income growth of % from the third quarter of 2025.

However, within the Healthcare sector 30 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 125.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 241.12 % 3.39 % 44.26 % -9.66 % -64.66 %
Y / Y Net Income Change -56.25 % - - - -53.7 %
Net Income (TTM) in million 1 3 3 3 3
Return On Assets (TTM) 1.95 % 9.95 % 10.01 % 10.58 % 10.41 %
GLMD's Total Ranking # 125 # # # # 113
Total Assets (TTM) in million 225 21 23 19 66
Seq. Total Assets Change 955.95 % -6 % 21.75 % -71.77 % 220.03 %
Seq. Net Income Change - - - - -

GLMD's 5 Years Annual ROA >> Back to GLMD Management Effectiveness >> Compare GLMD ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 13
Sector # 31
Overall # 121

Return On Assets Statistics
High Average Low
108.09 %
7.94 %
-103.06 %
(Dec 31 2022)   (Dec 31 2016)





Financial Statements
Galmed Pharmaceuticals Ltd 's Assets $ 225 million GLMD's Balance sheet
Galmed Pharmaceuticals Ltd 's Income $ 1 million Quarterly GLMD's Income Statement
GLMD's Income by Division See GLMD's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 241.12 % -64.66 % 8.73 % 3.61 % 173.47 %
Total Assets in million 225 66 187 172 166
Y / Y Net Income Change -8 % -27.18 % -42.46 % -44.75 % -
Net Income in million 7 8 10 18 32
Annual Return On Assets 3.07 % 11.37 % 5.52 % 10.42 % 19.55 %

GLMD's 5 Years Annual ROA >> Back to GLMD Management Effectiveness >> Compare GLMD ROA to its Competitors



Comment on GLMD's ROA in the fiscal year ending 2025
In the fiscal year 2025 Galmed Pharmaceuticals Ltd 's ROA decreased compared to previous year to 3.07 %, due to deterioration of net income -8 % to $6.90 million, from $7.50 million a year ago, as GLMD's assets were $225.10 million.


More Return On Assets Ratios
GLMD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GLMD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GLMD's Competitors
Subscribers only: Roa for Galmed Pharmaceuticals Ltd 's Suppliers
Subscribers only: Return On Assets for GLMD's Customers

You may also want to know
GLMD's Roi GLMD's Inventory Turnover Ratio GLMD's Growth Rates GLMD's Dividend Comparisons
GLMD's Profitability Ratios GLMD's Asset Turnover Ratio GLMD's Dividend Growth
GLMD's Roe GLMD's Valuation Ratios GLMD's Financial Strength Ratios GLMD's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Kamada Ltd   5.33 %
Medtronic Plc  5.07 %
Community Health Systems Inc   5.01 %
Xtant Medical Holdings Inc   4.98 %
Merit Medical Systems Inc  4.96 %
Veracyte Inc   4.88 %
U S Physical Therapy Inc  4.87 %
Organogenesis Holdings Inc   4.87 %
Labcorp Holdings Inc   4.85 %
Iqvia Holdings Inc   4.75 %
Biomarin Pharmaceutical Inc  4.68 %
Soleno Therapeutics Inc  4.61 %
Ardent Health Inc   4.52 %
Biogen Inc   4.50 %
Gyre Therapeutics Inc   4.40 %
Arcutis Biotherapeutics Inc   4.30 %
Fonar Corporation  4.27 %
The Pennant Group Inc   4.20 %
Beone Medicines Ltd   4.10 %
Bioventus Inc   3.92 %
Collegium Pharmaceutical Inc   3.88 %
Seres Therapeutics Inc   3.86 %
Fresenius Medical Care Ag  3.84 %
Henry Schein Inc   3.84 %
Pfizer Inc  3.76 %
Emergent Biosolutions Inc   3.74 %
Select Medical Holdings Corp  3.73 %
Vericel Corporation  3.67 %
Amneal Pharmaceuticals Inc   3.64 %
Teva Pharmaceutical Industries Limited  3.56 %

Date modified: 2026-08-29T01:15:13+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.